Bicycle Therapeutics, which derives its name from a novel class of medicines it develops, is riding its way toward a Nasdaq listing.
Bicycle is a clinical-stage biopharma company and uses a novel class of medicines known as bicycles: synthetic short peptides constrained to form two loops, which provides stability and selectivity.
This unique therapeutic modality combines the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule…..CLICK for complete article
